RAS Wild Type

8 clinical trials · Condition

Record	Firm	Date
Glutamine PET Imaging Colorectal Cancer (NCT03275974)	M.D. Anderson Cancer Center	2021-04-27
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NCT03983993)	Emory University	2019-10-15
Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer (NCT04561336)	University of Campania Luigi Vanvitelli	2018-08-10
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab (NCT03300609)	University of Southern California	2018-02-27
Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) (NCT03043950)	iOMEDICO AG	2017-01-25
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (NCT03263663)	PD Dr. med. Volker Heinemann	2017-01-01
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (NCT02292758)	Academic and Community Cancer Research United	2014-12-12
Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer (NCT02071069)	Tianshu Liu	2013-07-01

Every clearance here is in the API, with alerts when new ones post.